LifeStance Health Group (NASDAQ:LFST) Raised to Strong-Buy at Wall Street Zen

LifeStance Health Group (NASDAQ:LFST) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently weighed in on LFST. BTIG Research boosted their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, August 7th. JPMorgan Chase & Co. raised their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday. The Goldman Sachs Group assumed coverage on shares of LifeStance Health Group in a research report on Friday, June 5th. They issued a “neutral” rating and a $9.00 price objective on the stock. Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Finally, KeyCorp increased their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $12.12.

LifeStance Health Group Price Performance

LFST stock opened at $12.42 on Friday. The stock’s fifty day simple moving average is $10.39 and its two-hundred day simple moving average is $8.23. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. LifeStance Health Group has a 1-year low of $4.77 and a 1-year high of $12.76. The stock has a market cap of $4.82 billion, a P/E ratio of 95.55 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. During the same quarter in the prior year, the company earned ($0.01) EPS. The business’s revenue for the quarter was up 26.1% on a year-over-year basis. Analysts expect that LifeStance Health Group will post 0.15 EPS for the current year.

Insider Transactions at LifeStance Health Group

In related news, COO Lisa K. Miller sold 47,912 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the sale, the chief operating officer directly owned 281,289 shares in the company, valued at approximately $3,051,985.65. The trade was a 14.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the sale, the director directly owned 539,763 shares in the company, valued at approximately $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 14,629,850 shares of company stock worth $154,952,012. Insiders own 3.50% of the company’s stock.

Institutional Trading of LifeStance Health Group

Several hedge funds and other institutional investors have recently modified their holdings of LFST. Silversmith Partners I GP LLC bought a new position in LifeStance Health Group in the 4th quarter worth about $100,842,000. First Eagle Investment Management LLC increased its position in shares of LifeStance Health Group by 13.3% during the fourth quarter. First Eagle Investment Management LLC now owns 1,496,466 shares of the company’s stock valued at $10,535,000 after buying an additional 176,000 shares during the period. Moran Wealth Management LLC bought a new stake in shares of LifeStance Health Group during the first quarter valued at about $953,000. Jennison Associates LLC lifted its holdings in shares of LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after buying an additional 2,843,388 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of LifeStance Health Group by 92.5% in the first quarter. Renaissance Technologies LLC now owns 800,500 shares of the company’s stock worth $5,099,000 after buying an additional 384,600 shares in the last quarter. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.